Track topics on Twitter Track topics that are important to you
Novimmune SA licensed Shire PLC exclusive global rights to develop and commercialize a bi-specific antibody for hemophilia A.
Shire has obtained exclusive worldwide rights from Novimmune for a bi-specific antibody that is currently in pre-clinical development for treating patients with the blood disorders hemophilia A and he...
Swiss biopharmaceutical company Novimmune has received rare paediatric disease designation for its lead drug emapalumab from the US Food and Drug Administration (FDA) to treat patients with primary ha...
Lexington, MA – July 18, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the biotech leader in Rare Diseases; and Novimmune S.A., a privately-held Swiss biopharmaceutical company focused on the discov...
Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva tha...
NovImmune SA ('NovImmune') is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders.
NovImmune SA (âNovImmuneâ) is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders. NovImmune...
We have published hundreds of NovImmune news stories on BioPortfolio along with dozens of NovImmune Clinical Trials and PubMed Articles about NovImmune for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NovImmune Companies in our database. You can also find out about relevant NovImmune Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...